The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities
Abstract
Cases of fatal, acute, irreversible renal failure and cytopenias, including agranulocytosis and thrombocytopenia, have been disclosed in a postmarketing report on deferasirox, a few months after the European Union authorities and about a year after the FDA proceeded to its accelerated approval. No details on the incidence rate or the cause of these toxicities have yet been reported. Other toxic side effects include skin, gastric, auditory and ocular abnormalities, and hepatitis. Regular serum creatinine, blood counts and other toxicity monitoring as well as withdrawal of deferasirox from the patients affected and those with serum ferritin < 0.5 mg/l was recommended. Toxicity, inability to clear cardiac iron and high cost (60 euros/g) question the future universal role of deferasirox, by comparison with the safety and efficacy records of deferiprone, deferoxamine and their combination in the treatment of transfusional iron overload. Also questioned are the procedures adopted by regulatory authorities and the marketing methods of pharmaceutical companies on orphan drugs, which are of no benefit to thalassaemia patients in developing countries.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“due to potential side‐effects of renal toxicity after repeated treatment, it is not ethically easy to apply this to humans who have been already exposed to asbestos.26, 27”
From Dual preventive benefits of iron elimination by desferal in asbestos‐induced mesothelial carcinogenesis (2016) · cites this paper as [26]
Citations
Cites
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR
Zurlo, M., De Stefano, P., Borgna-Pignatti, C., Di Palma, A., Melevendi, C., Piga, A., Di Gregorio, F., Burattini, M., & Terzoli, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90264-x · Cited by 611
Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
Modell, B., Khan, M., & Darlison, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 583
Pennell, D. J. (2006) · Blood · doi:10.1182/blood-2005-07-2948 · Cited by 495
Anderson, L. J., Westwood, M. A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J. B., Malcolm Walker, J., & Pennell, D. J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05202.x · Cited by 414
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06455.x · Cited by 271
Telfer, P. T., Coen, P. G., Christou, S., Hadjigavriel, M., Kolnakou, A., Pangalou, E., Pavlides, N., Psiloines, M., Simamonian, K., Skordos, G., et al. (2006) · PubMed · Cited by 190
Galanello, R., Piga, A. G., Alberti, D., Rouan, M. C., Bigler, H., & Séchaud, R. (2003) · PubMed · Cited by 169
Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670
Nick, H., Acklin, P., Lattmann, R., Buehlmayer, P., Hauffe, S., Schupp, J., & Alberti, D. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457610 · Cited by 168
Research works printed but not linked: 5
- 1983, WHO Bull., 61, 63
- TELFER, 2006, Haematologica, 91, 1187
- HENTER, 2007, Blood
- SHASHATY, 2006, Oncology, 20, 1799
- KONTOGHIORGHES, 1990, . Arzneimittel-Forschung/Drug Research, 40, 1332
Cited by
Leal, S. M., Roy, S., Vareechon, C., Carrion, S. D., Clark, H., Lopez-Berges, M. S., diPietro, A., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003436 · Cited by 111
Kontoghiorghes, G. J. (2008) · Hemoglobin · doi:10.1080/03630260701726533 · Cited by 49
Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yasui, H., & Toyokuni, S. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0244 · Cited by 39
Liu, J., Liu, W., Liu, Y., Miao, Y., Guo, Y., Song, H., Wang, F., Zhou, H., Ganz, T., Yan, B., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209874 · Cited by 30
Jiang, L., Chew, S., Nakamura, K., Ohara, Y., Akatsuka, S., & Toyokuni, S. (2016) · Cancer Science · doi:10.1111/cas.12947 · Cited by 19
Metadata
- Authors
- Kontoghiorghes, G. J.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2007-05
- Volume
- 6
- Issue
- 3
- Pages
- 235-239
- ISSN
- 1474-0338
- 1744-764X
- Cited by
- 62
- References
- 24
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. https://app.cochat.ai/papers/10.1517/14740338.6.3.235
- The paper
- Kontoghiorghes, G. J. (2007). Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.6.3.235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
